{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:53:12Z","timestamp":1793645592758,"version":"4.5.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,13]],"date-time":"2027-05-13T00:00:00Z","timestamp":1810166400000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA172382"],"award-info":[{"award-number":["R01CA172382"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA261995"],"award-info":[{"award-number":["R01CA261995"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA249279"],"award-info":[{"award-number":["R01CA249279"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.molmed.2025.07.004","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:14:55Z","timestamp":1753877695000},"page":"446-457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prostate cancer germline variants with therapeutic implications"],"prefix":"10.1016","volume":"32","author":[{"given":"Masoud","family":"Bitaraf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1281-3474","authenticated-orcid":false,"given":"Nima","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2025.07.004_bb0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2025.07.004_bb0010","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.molmed.2025.07.004_bb0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","article-title":"Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland","volume":"43","author":"Huggins","year":"1941","journal-title":"Arch. Surg."},{"key":"10.1016\/j.molmed.2025.07.004_bb0020","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s41585-024-00878-8","article-title":"Elevated periprostatic androgens, sneaky testosterone and its implications","volume":"21","author":"Bitaraf","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0025","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1200\/JCO.23.00433","article-title":"Targeting the androgen signaling axis in prostate cancer","volume":"41","author":"Dai","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0030","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.eururo.2024.12.007","article-title":"Heterogeneity of the treatment effect with PARP Inhibitors in metastatic castration-resistant prostate cancer: a living interactive systematic review and meta-analysis","volume":"87","author":"Naqvi","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0035","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.07.004_bb0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha Emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.07.004_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-025-00936-1","article-title":"Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy","author":"Gebrael","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.molmed.2025.07.004_bb0050","doi-asserted-by":"crossref","DOI":"10.1172\/JCI183583","article-title":"Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance","volume":"134","author":"Sharifi","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.07.004_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027130","article-title":"An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis","volume":"6","author":"Kici\u0144ski","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.molmed.2025.07.004_bb0060","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1158\/1055-9965.EPI-13-0568","article-title":"The heritability of prostate cancer in the Nordic Twin Study of Cancer","volume":"23","author":"Hjelmborg","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.molmed.2025.07.004_bb0065","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw110","article-title":"Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study","volume":"108","author":"Bratt","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.molmed.2025.07.004_bb0070","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nature08494","article-title":"Finding the missing heritability of complex diseases","volume":"461","author":"Manolio","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2025.07.004_bb0075","doi-asserted-by":"crossref","DOI":"10.4155\/fso.15.87","article-title":"Germline genetic profiling in prostate cancer: latest developments and potential clinical applications","volume":"2","author":"Ahmed","year":"2016","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.molmed.2025.07.004_bb0080","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.eururo.2022.12.021","article-title":"Genetic risk prediction for prostate cancer: implications for early detection and prevention","volume":"83","author":"Seibert","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","article-title":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction","volume":"53","author":"Conti","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2025.07.004_bb0090","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41588-024-02068-z","article-title":"Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups","volume":"57","author":"Hoffmann","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2025.07.004_bb0095","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1200\/JCO.22.01453","article-title":"CanRisk-Prostate: a comprehensive, externally validated risk model for the prediction of future prostate cancer","volume":"41","author":"Nyberg","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0100","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1634\/theoncologist.2015-0336","article-title":"The PROFILE feasibility study: targeted screening of men with a family history of prostate cancer","volume":"21","author":"Castro","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.molmed.2025.07.004_bb0105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.eururo.2015.09.038","article-title":"Prostate single nucleotide polymorphism provides a crucial clue to cancer aggression in active surveillance patients","volume":"69","author":"Cooper","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0110","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/ng.3020","article-title":"A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1","volume":"46","author":"Fachal","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2025.07.004_bb0115","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/bjc.2016.94","article-title":"Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity","volume":"114","author":"Ahmed","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molmed.2025.07.004_bb0120","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","article-title":"A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer","volume":"154","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2025.07.004_bb0125","doi-asserted-by":"crossref","first-page":"e242976","DOI":"10.1001\/jamanetworkopen.2024.2976","article-title":"Adrenal-permissive germline HSD3B1 allele and prostate cancer outcomes","volume":"7","author":"McKay","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.molmed.2025.07.004_bb0130","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molmed.2025.07.004_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189783","article-title":"Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic","volume":"22","author":"Ghose","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2025.07.004_bb0140","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","article-title":"Elevated risk of prostate cancer among men with lynch syndrome","volume":"31","author":"Raymond","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0145","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mdv004","article-title":"Prevalence of theHOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes","volume":"26","author":"Kote-Jarai","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.07.004_bb0155","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0160","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.eururo.2021.09.029","article-title":"Association of Inherited mutations in DNA repair genes with localized prostate cancer","volume":"81","author":"Lee","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0165","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0170","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial","volume":"42","author":"Mateo","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0175","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0180","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf025","article-title":"Response to pembrolizumab in advanced prostate cancer with predictive biomarkers","volume":"30","author":"Altomare","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.molmed.2025.07.004_bb0185","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.2217\/fon-2019-0068","article-title":"Clinical implications of mismatch repair deficiency in prostate cancer","volume":"15","author":"Sedhom","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0190","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/14728222.2021.1951226","article-title":"Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology","volume":"25","author":"Boussios","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.molmed.2025.07.004_bb0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.molmed.2025.07.004_bb0200","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1126\/science.8091231","article-title":"Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13","volume":"265","author":"Wooster","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.molmed.2025.07.004_bb0205","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.molmed.2025.07.004_bb0210","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1001\/jamaoncol.2024.2185","article-title":"BRCA1, BRCA2, and associated cancer risks and management for male patients: a review","volume":"10","author":"Cheng","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0215","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/1568009623666230209121732","article-title":"Advances in ovarian cancer treatment beyond PARP inhibitors","volume":"23","author":"Fine","year":"2023","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.molmed.2025.07.004_bb0220","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.7150\/jca.30410","article-title":"BRCA genes: the role in genome stability, cancer stemness and therapy resistance","volume":"10","author":"Gorodetska","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.molmed.2025.07.004_bb0225","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1158\/1541-7786.MCR-09-0123","article-title":"PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2","volume":"7","author":"Zhang","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.molmed.2025.07.004_bb0230","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1038\/sj.onc.1209874","article-title":"The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability","volume":"25","author":"Gudmundsdottir","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.molmed.2025.07.004_bb0235","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1042\/BST0340633","article-title":"Cellular functions of the BRCA tumour-suppressor proteins","volume":"34","author":"Boulton","year":"2006","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.molmed.2025.07.004_bb0240","article-title":"BRCA1 and BRCA2 mutations and treatment strategies for breast cancer","volume":"4","author":"Godet","year":"2017","journal-title":"Integr. Cancer Sci. Ther."},{"key":"10.1016\/j.molmed.2025.07.004_bb0245","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1200\/JCO.2016.67.0554","article-title":"Population frequency of germline BRCA1\/2 mutations","volume":"34","author":"Maxwell","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0250","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.21037\/tau-23-107","article-title":"Technologic advances in robot-assisted nephron sparing surgery: a narrative review","volume":"12","author":"Thakker","year":"2023","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0255","doi-asserted-by":"crossref","first-page":"54","DOI":"10.6004\/jnccn.2021.7010","article-title":"Inherited mutations in Chinese men with prostate cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.molmed.2025.07.004_bb0260","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2012.146","article-title":"Germline BRCA1 mutations increase prostate cancer risk","volume":"106","author":"Leongamornlert","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molmed.2025.07.004_bb0265","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0270","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0275","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0280","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0285","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2017.02.023","article-title":"Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer","volume":"72","author":"Annala","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0290","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.eururo.2018.01.010","article-title":"Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study","volume":"73","author":"Mateo","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0295","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2018.01.035","article-title":"Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide","volume":"74","author":"Antonarakis","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0300","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0305","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2025.07.004_bb0310","doi-asserted-by":"crossref","first-page":"S638","DOI":"10.1016\/j.annonc.2021.08.1103","article-title":"590P PRORADIUM: prospective analysis of the impact of germline mutations in homologous recombination (HR) genes on the response to radium-223 for metastatic castration resistant prostate cancer (mCRPC)","volume":"32","author":"Castro","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0315","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2020.05.001","article-title":"Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer","volume":"136","author":"van der Doelen","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.molmed.2025.07.004_bb0320","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0325","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2019.37.7_suppl.272","article-title":"Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy","volume":"37","author":"Conteduca","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0330","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","article-title":"Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors?","volume":"15","author":"Ashworth","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0335","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40268-020-00301-8","article-title":"Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond","volume":"20","author":"Boussios","year":"2020","journal-title":"Drugs R D"},{"key":"10.1016\/j.molmed.2025.07.004_bb0340","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.07.004_bb0345","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.07.004_bb0350","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial\u2606","volume":"34","author":"Chi","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0355","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2025.07.004_bb0360","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.molmed.2025.07.004_bb0365","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0370","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102293","article-title":"Activity of platinum chemotherapy in men with prostate cancer with and without DNA damage repair mutations","volume":"23","author":"Lakritz","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.molmed.2025.07.004_bb0380","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euo.2023.09.001","article-title":"Poly (ADP-ribose) polymerase inhibitors have comparable efficacy with platinum chemotherapy in patients with BRCA-positive metastatic castration-resistant prostate cancer. A systematic review and meta-analysis","volume":"7","author":"Fazekas","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0385","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41391-022-00626-2","article-title":"Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients\u2014a systematic review and meta-analysis","volume":"26","author":"Fazekas","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.molmed.2025.07.004_bb0390","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13668","article-title":"Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer","volume":"7","author":"Henzler","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.07.004_bb0395","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1210\/mend.24.7.9997","article-title":"A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. results from the national cancer institute breast and prostate cancer cohort consortium","volume":"24","author":"Lindstr\u00f6m","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0400","first-page":"2241","article-title":"Germline mutations and polymorphisms of androgen receptor in prostate cancer patients: frequency and results of in silico analysis","volume":"19","author":"Sribudiani","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.molmed.2025.07.004_bb0405","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2025.07.004_bb0410","doi-asserted-by":"crossref","first-page":"e243402","DOI":"10.1001\/jamanetworkopen.2024.3402","article-title":"Adrenal-permissive HSD3B1 genotype\u2014an invisible stimulator of prostate cancer mortality","volume":"7","author":"Schiffer","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.molmed.2025.07.004_bb0415","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41585-024-00953-0","article-title":"HSD3B1, prostate cancer mortality and modifiable outcomes","volume":"22","author":"Freitas","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0420","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S1470-2045(16)30227-3","article-title":"HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study","volume":"17","author":"Hearn","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0425","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2017.0147","article-title":"Independent validation of effect of HSD3B1 genotype on response to androgen-deprivation therapy in prostate cancer","volume":"3","author":"Agarwal","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0430","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/pros.22967","article-title":"Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer","volume":"75","author":"Wu","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.molmed.2025.07.004_bb0435","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaoncol.2017.3164","article-title":"Association of HSD3B1 genotype with response to androgen-deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer","volume":"4","author":"Hearn","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0440","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.annonc.2020.04.473","article-title":"Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype","volume":"31","author":"Lu","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0445","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.annonc.2020.06.006","article-title":"HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies","volume":"31","author":"Khalaf","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0450","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0455","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.annonc.2020.06.009","article-title":"Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean?","volume":"31","author":"Sharifi","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0460","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.6496","article-title":"HSD3B1 genotype and clinical outcomes in metastatic castration-sensitive prostate cancer","volume":"6","author":"Hearn","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molmed.2025.07.004_bb0465","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165718","article-title":"Intratumoral androgen biosynthesis associated with 3\u03b2-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer","volume":"133","author":"Ganguly","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.07.004_bb0470","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163498","article-title":"BMX controls 3\u03b2HSD1 and sex steroid biosynthesis in cancer","volume":"133","author":"Li","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.07.004_bb0475","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1158\/0008-5472.CAN-17-3615","article-title":"BMX-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer","volume":"78","author":"Chen","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2025.07.004_bb0480","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1210\/en.2010-0138","article-title":"3\u03b2-Hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer","volume":"151","author":"Evaul","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmed.2025.07.004_bb0485","article-title":"Management of prostate cancer by targeting 3\u03b2HSD1 after enzalutamide and abiraterone treatment","volume":"3","author":"Mei","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.molmed.2025.07.004_bb2005","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2422267122","article-title":"Fine structural design of 3\u03b2HSD1 inhibitors for prostate cancer therapy","volume":"122","author":"He","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425001704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425001704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:06:46Z","timestamp":1778760406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491425001704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1471491425001704"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2025.07.004","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate cancer germline variants with therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2025.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}